[4-(苯氧基甲基)苯基]甲醇 | 262862-97-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: [4-(苯氧基甲基)苯基]甲醇
• 英文名称: 4-phenoxymethylphenylmethanol
• 英文别名: 4-phenoxymethylbenzylalcohol；p-Xylylenglykol-monophenylaether；4-Phenoxymethyl-benzylalkohol；ω-Oxy-ω'-phenoxy-p-xylol；[4-(Phenoxymethyl)phenyl]methanol
• CAS: 262862-97-5
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: MTQHORUPINPVTP-UHFFFAOYSA-N

物化性质

• 熔点：
  106 °C
• 沸点：
  215-220 °C(Press: 13 Torr)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [4-(苯氧基甲基)苯基]甲醇 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以81%的产率得到4-(苯氧基甲基)苯甲醛
  参考文献：
  名称：

  [EN] CARBOXAMIDES DERIVATIVES
  [FR] DERIVES DE CARBOXAMIDES

  摘要：

  本发明涉及作为药物制剂活性成分有用的羧酰胺。本发明的羧酰胺具有IP受体拮抗活性，可用于预防和治疗与IP受体拮抗活性相关的疾病。这些疾病包括泌尿系统疾病或障碍，如：膀胱出口梗阻、膀胱过度活跃、尿失禁、膀胱逼尿肌过度反射、膀胱逼尿肌不稳定、膀胱容量减少、排尿频率、迫切性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺肥大（BPH）、前列腺炎、尿频、夜尿频、尿急、盆腔过敏、尿道炎、盆腔疼痛综合征、前列腺疼痛综合征、膀胱炎或特发性膀胱过敏。本发明的化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病性疼痛、急性疼痛、慢性疼痛、牙痛、经前疼痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为通过IP受体拮抗剂治疗可以缓解这些疾病。

  公开号：

  WO2003106403A1
• 作为产物：
  描述：

  4-(苯氧基甲基)苯甲醛 在 sodium tetrahydroborate 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 [4-(苯氧基甲基)苯基]甲醇
  参考文献：
  名称：

  Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

  摘要：

  A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: <0.008-8 mu g/mL), although they are generally less active than the references against the Gram-negative strains. In particular, compound 111 (MIC: <0.008-4 mu g/mL) was found to be 8-2048 and 2-128 times more potent than levofloxacin (LVFX) and GMFX against the Gram-positive strains, respectively. Moreover, against MRSA clinical isolates, 111 (MIC90: 1 mu g/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 mu g/mL). Crown Copyright (C) 2012 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.010

文献信息

• Asymmetric Guerbet Reaction to Access Chiral Alcohols
  作者：Kun Wang、Lin Zhang、Weijun Tang、Huaming Sun、Dong Xue、Ming Lei、Jianliang Xiao、Chao Wang

  DOI：10.1002/anie.202003104

  日期：2020.7.6

  example of an asymmetric Guerbet reaction has been developed. Using commercially available, classic Noyori RuII‐diamine‐diphosphine catalysts, well‐known in asymmetric hydrogenation, racemic secondary alcohols are shown to couple with primary alcohols in the presence of a base, affording new chiral alcohols with enantiomeric ratios of up to 99:1. Requiring no reducing agents, the protocol provides an easy

  已经开发出不对称Guerbet反应的第一个例子。使用在不对称氢化中众所周知的市售经典Noyori Ru II-二胺-二膦催化剂，外消旋仲醇在碱存在下与伯醇偶合，可提供对映体比例高达99的新型手性醇： 1。不需要还原剂，该方案为合成手性醇提供了一种简便的替代途径。机理研究表明，该反应是通过Ru催化的不对称氢自转移过程与碱促进的烯丙醇异构化协同进行的。
• Thiol compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06420415B1

  公开（公告）日：2002-07-16

  Compounds represented by general formula (1) or salts thereof which have a matrix metalloprotease inhibitory activity and are useful as drugs, wherein the rings A and B represent each an optionally substituted homocycle or heterocycle, etc.; R1s are the same or different and each represents hydrogen, optionally substituted hydrocarbyl, acyl, etc.; X1 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, etc.; X2 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, —O—, etc.; Ys are the same or different represents hydrogen, optionally substituted hydrocarbyl, oxo, etc.; m is 0 or 1; n is an integer of 1 to 3; q1 is an integer of 1 to 2n+4; and q2 is an integer of 0 to 2n+3, provided that q1+q2 is 2n+4.

  通式（1）表示的化合物或其盐具有基质金属蛋白酶抑制活性，并且可用作药物，其中环A和环B分别表示可选择取代的同环或异环等；R1s相同或不同，每个代表氢，可选择取代的烃基，酰基等；X1表示键，可选择取代的二价脂肪烃基等；X2表示键，可选择取代的二价脂肪烃基，—O—等；Ys相同或不同，代表氢，可选择取代的烃基，氧代，等；m为0或1；n为1到3的整数；q1为1到2n+4的整数；q2为0到2n+3的整数，前提是q1+q2为2n+4。
• Carboxylic acid derivatives as IP antagonists
  申请人：——

  公开号：US20010056100A1

  公开（公告）日：2001-12-27

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: 1 wherein: R 1 , R 2 , and R 3 are each independently in each occurrence aryl or heteroaryl; R 4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.

  这项发明涉及一类通常为IP受体拮抗剂的化合物，其由以下式I表示： 其中： R1、R2和R3在每次出现时各自独立地为芳基或杂环芳基； R4为—COOH或四唑基； A、B、m、n和r如规范中定义； 或其各个异构体、外消旋或非外消旋异构体混合物，或其药用可接受盐或溶剂合物。该发明还涉及含有这种化合物的药物组合物，以及将其用作治疗剂的方法和其制备方法。
• [EN] CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE UTILISES COMME DES ANTAGONISTES D'IP
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001068591A1

  公开（公告）日：2001-09-20

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula (I) wherein R?1, R2, and R3¿ are each independently in each occurrence aryl or heteroaryl, R4 is -COOH or tetrazolyl, A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, processes for their preparation and their use as therapeutic agents.

  本发明涉及一类化合物，通常为IP受体拮抗剂，其由式（I）表示，其中R1、R2和R3在每次出现时均独立地为芳基或杂环芳基，R4为-COOH或四唑基，A、B、m、n和r如规范中所定义；或其各个异构体，混合物，或其药学上可接受的盐或溶剂。本发明还涉及含有这种化合物的药物组合物，其制备方法以及作为治疗剂的用途。
• Carboxamides derivatives
  申请人：Shimazaki Makoto

  公开号：US20060135613A1

  公开（公告）日：2006-06-22

  The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

  本发明涉及一种作为制药制剂活性成分有用的羧酰胺。本发明的羧酰胺具有IP受体拮抗活性，可用于预防和治疗与IP受体拮抗活性相关的疾病。这些疾病包括以下泌尿系统疾病或疾病：膀胱出口梗阻、过度活动的膀胱、尿失禁、膀胱平滑肌过度反射、膀胱平滑肌不稳定、膀胱容量降低、排尿频率、强迫性尿失禁、压力性尿失禁、膀胱高反应性、良性前列腺增生症（BPH）、前列腺炎、尿频、夜尿、尿急、盆腔敏感性、尿道炎、盆腔疼痛综合征、前列腺痛、膀胱炎或特发性膀胱敏感性。本发明化合物还可用于治疗疼痛，包括但不限于炎症性疼痛、神经病理性疼痛、急性疼痛、慢性疼痛、牙痛、经前痛、内脏疼痛、头痛等；低血压；血友病和出血；以及炎症，因为这些疾病通过使用IP受体拮抗剂治疗得到缓解。